Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Nuvectis Pharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FORT LEE, N.J., AUG. 04, 2026 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT) ("NUVECTIS" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE THERAPIES FOR THE TREATMENT OF COMPLEMENT-RELATED CONDITIONS AND ONCOLOGY, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2026 AND PROVIDED AN UPDATE ON RECENT BUSINESS PROGRESS.

NUVECTIS PHARMA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

FIRST GLOBAL APPROVAL OF A ONCE-DAILY, ORALLY ADMINISTERED, COMPLEMENT FACTOR B INHIBITOR APPROVAL BASED ON ROBUST EFFICACY AND SAFETY DATA FROM HAISCO'S BROAD COMPLETED CLINICAL DEVELOPMENT PROGRAM IN PNH CIPROCOPAN APPLICATION FOR MARKETING APPROVAL IN CHINA FOR THE TREATMENT OF PATIENTS WITH PNH PREVIOUSLY TREATED WITH ANTI-C5 THERAPIES IS CURRENTLY UNDER REVIEW CIPROCOPAN HAS THE POTENTIAL TO BECOME AN EFFECTIVE THERAPY IN MULTIPLE COMPLEMENT-MEDIATED DISEASES AND PROVIDE A CONVENIENCE ADVANTAGE AS A ONCE-DAILY ORAL TREATMENT OPTION FOR PATIENTS REQUIRING CONTINUOUS LIFE-LONG TREATMENT FORT LEE, NJ, JULY 23, 2026 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT) (NUVECTIS OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE THERAPIES FOR THE TREATMENT OF COMPLEMENT-RELATED CONDITIONS AND ONCOLOGY, TODAY ANNOUNCED THAT CIPROCOPAN (NXP100), A ONCE-DAILY ORAL COMPLEMENT FACTOR B INHIBITOR, RECEIVED MARKETING APPROVAL FROM THE NATIONAL MEDICINAL PRODUCTS ADMINISTRATION OF CHINA (NMPA) FOR THE TREATMENT OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PREVIOUSLY UNTREATED WITH COMPLEMENT INHIBITORS (TREATMENT NAIVE). AS THE WORLD'S FIRST APPROVED ONCE-DAILY ORAL COMPLEMENT FACTOR B INHIBITOR, CIPROCOPAN OFFERS PATIENTS LIVING WITH PNH A NEW, EFFECTIVE, SAFE AND CONVENIENT TREATMENT OPTION AND PROVIDES IMPORTANT CLINICAL AND REGULATORY VALIDATION AND FURTHER SUPPORTS THE THERAPEUTIC POTENTIAL OF ONCE-DAILY ORAL FACTOR B INHIBITION IN PNH AND OTHER COMPLEMENT MEDIATED DISEASES.

CORRECTION: (TITLE CORRECTION) NUVECTIS ANNOUNCES MARKETING APPROVAL OF CIPROCOPAN (NXP100) IN CHINA FOR THE TREATMENT OF PATIENTS WITH PNH PREVIOUSLY UNTREATED WITH COMPLEMENT INHIBITORS

FORT LEE, NJ, JULY 23, 2026 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT) (NUVECTIS OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE THERAPIES FOR THE TREATMENT OF COMPLEMENT-RELATED CONDITIONS AND ONCOLOGY, TODAY ANNOUNCED THAT CIPROCOPAN (NXP100), A ONCE-DAILY ORAL COMPLEMENT FACTOR B INHIBITOR, RECEIVED MARKETING APPROVAL FROM THE NATIONAL MEDICINAL PRODUCTS ADMINISTRATION OF CHINA (NMPA) FOR THE TREATMENT OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PREVIOUSLY UNTREATED WITH COMPLEMENT INHIBITORS (TREATMENT NAIVE).

CIPROCOPAN (NXP100) RECEIVES MARKETING APPROVAL IN CHINA FOR THE TREATMENT OF PATIENTS WITH PNH PREVIOUSLY UNTREATED WITH COMPLEMENT INHIBITORS

NEW REPORT COVERS NUVECTIS PHARMA (NASDAQ: NVCT) AS THE COMPANY TRANSITIONS FROM A SINGLE-DRUG ONCOLOGY STORY INTO A LATE-STAGE RARE-DISEASE PLAYER FOLLOWING ITS JUNE LICENSING DEAL WITH HAISCO PHARMACEUTICAL GROUP. REPORT HIGHLIGHTS: NUVECTIS PHARMA (NASDAQ: NVCT) RECENTLY SECURED WORLDWIDE RIGHTS OUTSIDE CHINA TO NXP100, A POTENTIALLY BEST-IN-CLASS ONCE-DAILY ORAL THERAPY FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH), ALONG WITH ONCOLOGY ASSET NXP200, FROM HAISCO PHARMACEUTICAL GROUP.

STREETWATCH: NUVECTIS PHARMA EYES $9.8 BILLION ORAL PNH MARKET WITH LATE-STAGE NXP100 BACKED BY STRONG POSITIVE PHASE 3 DATA

FORT LEE, N.J., JUNE 29, 2026 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE THERAPIES FOR THE TREATMENT OF IMMUNE COMPLEMENT-RELATED CONDITIONS AND ONCOLOGY, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 5,000,000 SHARES OF ITS COMMON STOCK AT A PRICE OF $20.00 PER SHARE, WITH EXPECTED GROSS PROCEEDS TO NUVECTIS OF $100 MILLION. NUVECTIS HAS ALSO GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO 750,000 ADDITIONAL SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT JULY 1, 2026, SUBJECT TO SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

NUVECTIS PHARMA ANNOUNCES PRICING OF $100 MILLION PUBLIC OFFERING OF COMMON STOCK

FORT LEE, NJ, JUNE 29, 2026 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE THERAPIES FOR THE TREATMENT OF IMMUNE COMPLEMENT-RELATED CONDITIONS AND ONCOLOGY, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK. ALL OF THE SHARES TO BE SOLD IN THE OFFERING WILL BE OFFERED BY NUVECTIS. IN ADDITION, NUVECTIS INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 15% OF THE SHARES OF ITS COMMON STOCK OFFERED IN THE PUBLIC OFFERING. THE OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

NUVECTIS PHARMA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

FORT LEE, NJ, JUNE 22, 2026 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT) (NUVECTIS OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE THERAPIES FOR THE TREATMENT OF COMPLEMENT-RELATED CONDITIONS AND ONCOLOGY, TODAY ANNOUNCED A STRATEGIC PORTFOLIO EXPANSION VIA A LICENSE AGREEMENT FOR EXCLUSIVE EX-CHINA RIGHTS WITH HAISCO PHARMACEUTICAL GROUP (HAISCO) TO TWO POTENTIALLY BEST IN-CLASS CLINICAL-STAGE COMPOUNDS. NUVECTIS WILL HOLD A CONFERENCE CALL TODAY AT 8:30 AM ET TO INTRODUCE ITS NEWLY IN-LICENSED PRODUCTS.

NUVECTIS ANNOUNCES STRATEGIC PORTFOLIO EXPANSION VIA LICENSE AGREEMENT FOR EX-CHINA RIGHTS WITH HAISCO PHARMACEUTICAL GROUP FOR TWO POTENTIALLY BEST-IN CLASS CLINICAL-STAGE COMPOUNDS

FORT LEE, NJ, MAY 14, 2026 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT) ("NUVECTIS" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE PRECISION MEDICINES FOR THE TREATMENT OF SERIOUS CONDITIONS OF UNMET MEDICAL NEED IN ONCOLOGY, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE H.C. WAINWRIGHT 4TH ANNUAL BIOCONNECT INVESTOR CONFERENCE AT NASDAQ ON TUESDAY, MAY 19, 2026 IN NEW YORK.

NUVECTIS PHARMA, INC. TO PARTICIPATE IN THE H.C. WAINWRIGHT 4TH ANNUAL BIOCONNECT INVESTOR CONFERENCE AT NASDAQ

FORT LEE, N.J., MAY 05, 2026 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT) ("NUVECTIS" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE PRECISION MEDICINES FOR THE TREATMENT OF SERIOUS CONDITIONS OF UNMET MEDICAL NEED IN ONCOLOGY, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2026 AND PROVIDED AN UPDATE ON RECENT BUSINESS PROGRESS.

NUVECTIS PHARMA, INC. REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

FORT LEE, NJ, MARCH 31, 2026 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT) ("NUVECTIS" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE PRECISION MEDICINES FOR THE TREATMENT OF SERIOUS CONDITIONS OF UNMET MEDICAL NEED IN ONCOLOGY, TODAY ANNOUNCED UPCOMING PRESENTATIONS FOR NXP900 AT THE UPCOMING 2026 AMERICAN ASSOCIATION FOR CANCER RESEARCH MEETING (2026 AACR), TAKING PLACE FROM APRIL 17TH TO APRIL 22ND IN SAN DIEGO, CA.

Nuvectis Pharma, Inc.

NVCT

Price

Financial Reports

No items found.

Press Releases

Nuvectis Pharma, Inc.

NVCT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NVCT